In a second trial ( NCT00478621 ) , subjects received control or one of 5 tetravalent HPV-16 / 18/33/58 vaccines formulated with different adjuvant systems ( AS04 , AS01 or AS02 ) , administered on different schedules ( M0 ,1,6 or M0 ,3 or M0 ,6 ) .